Chemotherapy stimulates syndecan-1 shedding: A potentially negative effect of treatment that may promote tumor relapse

Matrix Biology

Volumn 35, Issue , 2014, Pages 215-222

  Ramani, Vishnu C ^a   Sanderson, Ralph D ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Batimastat; Chemotherapy; Hepatocyte growth factor; Multiple myeloma; Shed syndecan 1; Shedding

Indexed keywords

ADAM PROTEIN; BATIMASTAT; SMALL INTERFERING RNA; SYNDECAN 1; ANTINEOPLASTIC AGENT; CASPASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; PRIMER DNA; SDC1 PROTEIN, HUMAN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL SURFACE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RELAPSE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BIOSYNTHESIS; BLOOD; BONE MARROW; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; WESTERN BLOTTING;

ANIMALIA;

ADAM PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BONE MARROW; CASPASE INHIBITORS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MULTIPLE MYELOMA; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE; SYNDECAN-1; TETRAZOLIUM SALTS; THIAZOLES; TUMOR MICROENVIRONMENT;

EID: 84901413320     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2013.10.005     Document Type: Article

References (44)

1. Bass M.D., Morgan M.R., Humphries M.J. Syndecans shed their reputation as inert molecules. Sci. Signal. 2009, 2:pe18.
2. Bayer-Garner I.B., Sanderson R.D., Dhodapkar M.V., Owens R.B., Wilson C.S. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod. Pathol. 2001, 14:1052-1058.
3. Beauvais D.M., Rapraeger A.C. Syndecans in tumor cell adhesion and signaling. Reprod. Biol. Endocrinol. 2004, 2:3.
4. Bernfield M., Kokenyesi R., Kato M., Hinkes M.T., Spring J., Gallo R.L., Lose E.J. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 1992, 8:365-393.
5. Borset M., Hjorth-Hansen H., Seidel C., Sundan A., Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996, 88:3998-4004.
6. Carvalho C., Santos R.X., Cardoso S., Correia S., Oliveira P.J., Santos M.S., Moreira P.I. Doxorubicin: the good, the bad and the ugly effect. Curr. Med. Chem. 2009, 16:3267-3285.
7. Choi S., Lee H., Choi J.R., Oh E.S. Shedding; towards a new paradigm of syndecan function in cancer. BMB Rep. 2010, 43:305-310.
8. Derksen P.W., de Gorter D.J., Meijer H.P., Bende R.J., van Dijk M., Lokhorst H.M., Bloem A.C., Spaargaren M., Pals S.T. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003, 17:764-774.
9. Ding K., Lopez-Burks M., Sanchez-Duran J.A., Korc M., Lander A.D. Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J. Cell Biol. 2005, 171:729-738.
10. Gaida M.M., Haag N., Gunther F., Tschaharganeh D.F., Schirmacher P., Friess H., Giese N.A., Schmidt J., Wente M.N. Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int. J. Mol. Med. 2010, 26:281-288.
11. Goffin L., Seguin-Estevez Q., Alvarez M., Reith W., Chizzolini C. Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts. Arthritis Res. Ther. 2010, 12:R73.
12. Gotte M., Kersting C., Ruggiero M., Tio J., Tulusan A.H., Kiesel L., Wulfing P. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res. 2006, 26:621-627.
13. Hayashida K., Bartlett A.H., Chen Y., Park P.W. Molecular and cellular mechanisms of ectodomain shedding. Anat. Rec. 2010, 293:925-937.
14. Hayashida K., Stahl P.D., Park P.W. Syndecan-1 ectodomain shedding is regulated by the small GTPase Rab5. J. Biol. Chem. 2008, 283:35435-35444.
15. Hjertner O., Torgersen M.L., Seidel C., Hjorth-Hansen H., Waage A., Borset M., Sundan A. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 1999, 94:3883-3888.
16. Joensuu H., Anttonen A., Eriksson M., Makitaro R., Alfthan H., Kinnula V., Leppa S. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res. 2002, 62:5210-5217.
17. Jourdan M., Ferlin M., Legouffe E., Horvathova M., Liautard J., Rossi J.F., Wijdenes J., Brochier J., Klein B. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br. J. Haematol. 1998, 100:637-646.
18. Kliment C.R., Englert J.M., Gochuico B.R., Yu G., Kaminski N., Rosas I., Oury T.D. Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis. J. Biol. Chem. 2009, 284:3537-3545.
19. Kyula J.N., Van Schaeybroeck S., Doherty J., Fenning C.S., Longley D.B., Johnston P.G. Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin. Cancer Res. 2010, 16:3378-3389.
20. Lamorte S., Ferrero S., Aschero S., Monitillo L., Bussolati B., Omede P., Ladetto M., Camussi G. Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. Leukemia 2012, 26:1081-1090.
21. Li Q., Park P.W., Wilson C.L., Parks W.C. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002, 111:635-646.
22. Lonial S., Mitsiades C.S., Richardson P.G. Treatment options for relapsed and refractory multiple myeloma. Clin. Cancer Res. 2011, 17:1264-1277.
23. Manon-Jensen T., Itoh Y., Couchman J.R. Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J. 2010, 277:3876-3889.
24. Nikolova V., Koo C.Y., Ibrahim S.A., Wang Z., Spillmann D., Dreier R., Kelsch R., Fischgrabe J., Smollich M., Rossi L.H., Sibrowski W., Wulfing P., Kiesel L., Yip G.W., Gotte M. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009, 30:397-407.
25. Paramore A., Frantz S. Bortezomib. Nat. Rev. Drug Discov. 2003, 2:611-612.
26. Park P.W., Pier G.B., Hinkes M.T., Bernfield M. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 2001, 411:98-102.
27. Park P.W., Pier G.B., Preston M.J., Goldberger O., Fitzgerald M.L., Bernfield M. Syndecan-1 shedding is enhanced by LasA, a secreted virulence factor of Pseudomonas aeruginosa. J. Biol. Chem. 2000, 275:3057-3064.
28. Pruessmeyer J., Martin C., Hess F.M., Schwarz N., Schmidt S., Kogel T., Hoettecke N., Schmidt B., Sechi A., Uhlig S., Ludwig A. A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells. J. Biol. Chem. 2010, 285:555-564.
29. Purushothaman A., Chen L., Yang Y., Sanderson R.D. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J. Biol. Chem. 2008, 283:32628-32636.
30. Purushothaman A., Hurst D.R., Pisano C., Mizumoto S., Sugahara K., Sanderson R.D. Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J. Biol. Chem. 2011, 286:30377-30383.
31. Purushothaman A., Uyama T., Kobayashi F., Yamada S., Sugahara K., Rapraeger A.C., Sanderson R.D. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010, 115:2449-2457.
32. Ramani V.C., Pruett P.S., Thompson C.A., DeLucas L.D., Sanderson R.D. Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J. Biol. Chem. 2012, 287:9952-9961.
33. Ramani V.C., Purushothaman A., Stewart M.D., Thompson C.A., Vlodavsky I., Au J.L., Sanderson R.D. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. 2013, 280:2294-2306.
34. Ramani V.C., Yang Y., Ren Y., Nan L., Sanderson R.D. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J. Biol. Chem. 2011, 286:6490-6499.
35. Reiland J., Ott V.L., Lebakken C.S., Yeaman C., McCarthy J., Rapraeger A.C. Pervanadate activation of intracellular kinases leads to tyrosine phosphorylation and shedding of syndecan-1. Biochem. J. 1996, 319:39-47.
36. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3:1101-1108.
37. Seidel C., Sundan A., Hjorth M., Turesson I., Dahl I.M., Abildgaard N., Waage A., Borset M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000, 95:388-392.
38. Su G., Blaine S.A., Qiao D., Friedl A. Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J. Biol. Chem. 2007, 282:14906-14915.
39. Tagoug I., Plesa A., Dumontet C. Bortezomib influences the expression of malignant plasma cells membrane antigens. Eur. J. Pharmacol. 2013, 706:11-16.
40. Tokes A.M., Szasz A.M., Farkas A., Toth A.I., Dank M., Harsanyi L., Molnar B.A., Molnar I.A., Laszlo Z., Rusz Z., Kulka J. Stromal matrix protein expression following preoperative systemic therapy in breast cancer. Clin. Cancer Res. 2009, 15:731-739.
41. Vahdat A.M., Reiners K.S., Simhadri V.L., Eichenauer D.A., Boll B., Chalaris A., Simhadri V.R., Wiegmann K., Krell H.W., Rose-John S., Engert A., von Strandmann E.P., Hansen H.P. TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. Leukemia 2010, 24:51-57.
42. Yang Y., Macleod V., Bendre M., Huang Y., Theus A.M., Miao H.Q., Kussie P., Yaccoby S., Epstein J., Suva L.J., Kelly T., Sanderson R.D. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 2005, 105:1303-1309.
43. Yang Y., Macleod V., Miao H.Q., Theus A., Zhan F., Shaughnessy J.D., Sawyer J., Li J.P., Zcharia E., Vlodavsky I., Sanderson R.D. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J. Biol. Chem. 2007, 282:13326-13333.
44. Zhan F., Hardin J., Kordsmeier B., Bumm K., Zheng M., Tian E., Sanderson R., Yang Y., Wilson C., Zangari M., Anaissie E., Morris C., Muwalla F., van Rhee F., Fassas A., Crowley J., Tricot G., Barlogie B., Shaughnessy J. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002, 99:1745-1757.